UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the Month of: October 2017
Commission File Number: 001-37847
MOTIF BIO PLC
(Exact name of registrant as specified in its charter)
125 Park Avenue
25th Floor
New York, New York 10011
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
MOTIF BIO PLC
FORM 6-K
POSITIVE TOPLINE RESULTS FOR ICLAPRIM IN THE REVIVE-2 PHASE 3 STUDY
On October 4, 2017, Motif Bio plc issued a press release, a copy of which is attached as Exhibit 99.1 to this report on Form 6-K, announcing positive topline results from REVIVE-2, a global Phase 3 clinical trial evaluating the investigational drug candidate iclaprim in patients with acute bacterial skin and skin structure infections.
The information contained in Exhibit 99.1 is being furnished to the U.S. Securities and Exchange Commission (the “Commission”) and shall not be deemed incorporated by reference into any of the registrant’s registration statements or other filing with the Commission.
Exhibits
Exhibit 99.1 Press Release issued by Motif Bio plc, dated October 4, 2017, entitled “Motif Bio Announces Positive Topline Results for Iclaprim in the REVIVE-2 Phase 3 Study.”
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MOTIF BIO PLC |
| |
| By: | /s/ Graham Lumsden |
| Name: Graham Lumsden |
| Title: Chief Executive Officer |
Date: October 4, 2017
3
